

Take-Home Naloxone for the Emergency Interim Management of Opioid Use Disorder: A Public Health Application of an Emergency Medicine

Drugs

79, 1395-1418

DOI: [10.1007/s40265-019-01154-5](https://doi.org/10.1007/s40265-019-01154-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	30.5	278
2	Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e205-e214.	1.5	2
3	Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108265.	3.2	10
4	The missing link: Incorporating behaviour change theories in overdose education and naloxone distribution programs. <i>International Journal of Drug Policy</i> , 2020, 83, 102853.	3.3	1
5	Peripheral tetrahydrobiopterin is involved in the pathogenesis of mechanical hypersensitivity in a rodent postsurgical pain model. <i>Pain</i> , 2020, 161, 2520-2531.	4.2	3
6	Opioid Prescribing with Take-Home Naloxone: Rationale and Recommendations. <i>Current Anesthesiology Reports</i> , 2020, 10, 428-435.	2.0	3
7	US drug overdose mortality: 2009â€“2018 increases affect young people who use drugs. <i>International Journal of Drug Policy</i> , 2020, 85, 102906.	3.3	13
8	Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108099.	2.8	10
9	COVID-19 and the health of people who use drugs: What is and what could be?. <i>International Journal of Drug Policy</i> , 2020, 83, 102958.	3.3	74
10	Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS. <i>Pain Medicine</i> , 2020, 21, 2244-2252.	1.9	6
11	Generational trends in US opioid-overdose deaths. <i>Nature Medicine</i> , 2020, 26, 651-652.	30.7	8
12	The opioid epidemic in pediatrics: a 2020 update. <i>Current Opinion in Anaesthesiology</i> , 2020, 33, 327-334.	2.0	29
13	Addiction stigma and the production of impediments to take-home naloxone uptake. <i>Health (United Kingdom)</i> , 2020, 15, 27.	1.5	27
14	A systematic review of opioid overdose interventions delivered within emergency departments. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108009.	3.2	35
15	Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. <i>International Journal of Drug Policy</i> , 2020, 79, 102751.	3.3	15
16	Prevalence and disparities in opioid overdose response training among people who inject drugs, San Francisco. <i>International Journal of Drug Policy</i> , 2021, 90, 102778.	3.3	10
17	Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia. <i>International Journal of Drug Policy</i> , 2021, 90, 103061.	3.3	17
18	A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naïve children. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108425.	3.2	3

#	ARTICLE	IF	CITATIONS
19	A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.. International Journal of Drug Policy, 2021, 87, 102968.	3.3	5
20	Homelessness and Substance Use Disorders. , 2021, , 179-194.		3
21	Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids. Drugs: Education, Prevention and Policy, 0, , 1-12.	1.3	0
22	A Molecularly Imprinted Sol-Gel Electrochemical Sensor for Naloxone Determination. Nanomaterials, 2021, 11, 631.	4.1	12
23	Australian Community Pharmacy Harm-Minimisation Services: Scope for Service Expansion to Improve Healthcare Access. Pharmacy (Basel, Switzerland), 2021, 9, 95.	1.6	6
24	Application of Distributed Agent-based Modeling to Investigate Opioid Use Outcomes in Justice Involved Populations. , 2021, , .		2
25	The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases. Harm Reduction Journal, 2021, 18, 67.	3.2	9
26	Intranasal Naloxone Administration. New England Journal of Medicine, 2021, 384, e96.	27.0	1
27	Shifting the Paradigm: Patient-Centered Emergency Department Opioid Use Disorder Treatment. Annals of Emergency Medicine, 2021, 78, 80-83.	0.6	0
28	The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanyl in human volunteers. European Journal of Clinical Pharmacology, 2021, 77, 1901-1908.	1.9	5
29	Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study. International Journal of Drug Policy, 2021, 96, 103421.	3.3	5
30	Electrochemical Determination of Naloxone Using Molecularly Imprinted Poly(para-phenylenediamine) Sensor. Journal of the Electrochemical Society, 2020, 167, 137508.	2.9	15
31	Treating Non-fentanyl-derived Synthetic Opioid Overdose with a Traditional Opioid Reversal Agent. Cureus, 2020, 12, e7241.	0.5	1
32	Naloxone perspectives from people who use opioids: Findings from an ethnographic study in three states. Journal of the American Association of Nurse Practitioners, 2021, 33, 294-303.	0.9	9
33	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open, 2020, 10, e041556.	1.9	1
34	Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a "moral hazard"™ associated with naloxone supply. International Journal of Drug Policy, 2022, 100, 103513.	3.3	23
35	The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling study. Addiction, 2022, 117, 1009-1019.	3.3	5
36	NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open, 2020, 10, e041556.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Impact of participation in a peer-led overdose program for people who use drugs. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 259-268.	1.3	1
38	Piloting a statewide emergency department take-home naloxone program: Improving the quality of care for patients at risk of opioid overdose. <i>Academic Emergency Medicine</i> , 2022, 29, 442-455.	1.8	7
39	Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-blind, randomised, controlled trial. <i>Addiction</i> , 2022, 117, 1658-1667.	3.3	9
40	Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial. <i>Journal of General Internal Medicine</i> , 2022, 37, 2624-2633.	2.6	8
43	Predictors of severe outcome following opioid intoxication in children. <i>Clinical Toxicology</i> , 2022, , 1-6.	1.9	2
44	Opioid overdose, interventions, and challenges. <i>BioImpacts</i> , 2022, , .	1.5	0
45	An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine. <i>Bulletin of the World Health Organization</i> , 2022, 100, 187-195.	3.3	1
46	Assessment of knowledge and awareness regarding opioid overdose and toxicity among a sample of healthcare providers. <i>Pharmacy Education</i> , 0, , 265-275.	0.6	0
47	Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact. <i>European Addiction Research</i> , 2022, 28, 161-175.	2.4	6
48	Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose. <i>Journal of Substance Abuse Treatment</i> , 2022, 139, 108785.	2.8	4
49	Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 203-217.	3.3	4
50	Enhancing research data infrastructure to address the opioid epidemic: the Opioid Overdose Network (O2-Net). <i>JAMIA Open</i> , 2022, 5, .	2.0	1
51	Drug use behaviors, trauma, and emotional affect following the overdose of a social network member: A qualitative investigation. <i>International Journal of Drug Policy</i> , 2022, 107, 103792.	3.3	6
52	Implementing a Novel Statewide Network to Support Emergency Department-initiated Buprenorphine Treatment. <i>Western Journal of Emergency Medicine</i> , 2022, 23, 451-460.	1.1	3
53	Preventing nausea and vomiting after gynecological laparoscopic surgery by patient-controlled intravenous analgesia with a naloxone admixture: A randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, 100781.	1.0	0
54	Patient perspectives on naloxone receipt in the emergency department: a qualitative exploration. <i>Harm Reduction Journal</i> , 2022, 19, .	3.2	1
55	The onset and severity of acute opioid toxicity in heroin overdose cases: a retrospective cohort study at a supervised injecting facility in Melbourne, Australia. <i>Clinical Toxicology</i> , 2022, 60, 1227-1234.	1.9	2
56	Synthetic Opioid Novel Psychoactive Substances (Fentanyl and Non-fentanyl). , 2022, , 78-100.		0

#	ARTICLE	IF	CITATIONS
57	Fatalities in Patients with Opioid Use Disorders. , 2022, , 1851-1867.		0
58	Implementation facilitators and barriers to the expansion of a peer-led overdose prevention program. Drugs: Education, Prevention and Policy, 0, , 1-9.	1.3	1
59	Improving access to naloxone and opioid resources through the emergency department. American Journal of Emergency Medicine, 2023, 68, 201-205.	1.6	0
62	“It can save your life, that’s all I know,” barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study. Qualitative Research in Medicine & Healthcare, 2023, 7, .	0.2	1
63	A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS. BMC Public Health, 2023, 23, .	2.9	1
64	Characterization of Illicit Drugs by Surface-Enhanced Raman Spectroscopy (SERS) and Principal Component Analysis (PCA). Analytical Letters, 0, , 1-14.	1.8	0
65	“Naloxone? Not for me!” First cross-assessment by patients and healthcare professionals of the risk of opioid overdose. Harm Reduction Journal, 2024, 21, .	3.2	0
66	Overview of best practices for buprenorphine initiation in the emergency department. International Journal of Emergency Medicine, 2024, 17, .	1.6	0
67	Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clinical Pharmacokinetics, 2024, 63, 397-422.	3.5	0